Arnold Ventures

because, you know, there's just not that much interest.

You know, I'm very grateful that the campaign works with groups like Arnold Ventures who do these kinds of grants.

NCPG has a great, you know, relationship with the NFL where they're providing a couple million dollars a year, but like a couple million dollars doesn't go that far.

So the problem we have, and I think it's an international problem, is there's just not a lot of money for this and resources outside of the industry.

I know there's a lot of concern about the ability to sue.

My understanding from hearing really great podcast interviews with Daniel Palkin, who's now at Arnold Ventures, but spent years on the Hill working in the Senate on permitting.

He was on the Columbia Energy Exchange and the Volts podcast.

And really breaks down the bill and talks about how the ability to sue has not gone away.

Product cost goes through the roof.

So I asked my friend Dennis Calabrese, who's worked with the Arnold Foundation for some time, to help me understand this.

And he said, why don't I get you the guy who's the expert on it, Dan Liljenquist.

He's senior vice president and chief strategy officer for Intermountain Healthcare.

And that's become really a big problem in the market.

Well, and it seems like there's less price competition.

Going back to what you're doing here with Civica RX, the company, the not-for-profit company that the Arnold Foundation gave this money to, where is this, the money that y'all are receiving, is that going toward product development or is that going to subsidies? Because you talk about filling the need for people that can't afford these drugs.

So it is not going to subsidies.

That's Daniel Reif.

I'm looking at the funding for fulcrum.us, the Hewlett Foundation, as in Hewlett Packard, Arnold Ventures, not sure what that is, Craig Newark Philanthropies, Unite America Institute, the Gaia Fund, Lizzie and Jonathan M. Tisch Foundation, the Thornburg Foundation.

They also get support from an organization called Issue One, which says it's an incubation support and partnership.

A lot of these are cutouts.

Isabella Kulkarni provided additional production help.

Reporting for this story was supported in part by Arnold Ventures.

Listeners like you are our biggest source of support.

We need you more than ever.

Thanks to all our listeners who helped to support our work, including Lucy Stark, Laura Galbraith, Laura Kruitzer, Wenja Zhu, Michael Richards, and Jessica Solom.

Our media partner is SideFX Public Media, based at WFYI.

Tradeoffs is supported by the Robert Wood Johnson Foundation, Arnold Ventures, the Sozoze Foundation, the Foundation for Opioid Response Efforts, the National Institute for Healthcare Management Foundation, the California Healthcare Foundation, and the Leonard Davis Institute at the University of Pennsylvania.

Our financial supporters are not involved in any decisions about our journalism.

Our media partner is SideFX Public Media, based at WFYI.

Tradeoffs is supported by the Robert Wood Johnson Foundation, Arnold Ventures, the Sozoze Foundation, the Foundation for Opioid Response Efforts, the National Institute for Healthcare Management Foundation, the California Healthcare Foundation, and the Leonard Davis Institute at the University of Pennsylvania.

Our financial supporters are not involved in any decisions about our journalism.

The views expressed in this episode are those of the individuals and not those of Tradeoffs staff, advisors, or funders.

I'm excited to bring you on-the-ground interviews from the summit hosted by the Texas Nuclear Alliance in Houston, three days that brought together some of the most important people investing in, operating, and building nuclear energy in America.

Over the series, you'll hear from key players, including John Arnold of Arnold Ventures, Reed Clay of the Texas Nuclear Alliance, Rod Adams of Nucleation Capital, and several others.

We filmed throughout, so be sure to watch on YouTube or Spotify.

I think you're really gonna enjoy the series.